Skip to content
value.today

IRX Therapeutics Inc

Total raised
$109 M
8 rounds on record
Latest round
$33 M
Dec 2016
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of IRX Therapeutics Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$33 MNo. 8$10 to $50 million

IRX Therapeutics Inc: Raise no. 8, Dec 2016

Investors in this round

98 investors had bought by the notice of Aug 29, 2017: 98 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$33 M of $33 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis P. Robb · Executive Officer
  • Mark W. Leuchtenberger · Executive Officer, Director
  • Monil W. Shah · Executive Officer
  • Zygmund P. Roth · Executive Officer
  • Charles R. Cherington · Director
  • David H. Deming · Director
  • Edmund W. Truell · Director
  • Ferid D. Murad · Director
  • George P. Denny III · Director
  • John D. Halpern · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 29, 2017. Read the notice at the SEC.

equitySEC
Oct 2016$6 MNo. 7$2 to $10 million

IRX Therapeutics Inc: Raise no. 7, Oct 2016

Investors in this round

4 investors had bought by the notice of Nov 9, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis P. Robb · Executive Officer
  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer, Director
  • Zygmund P. Roth · Executive Officer
  • Charles R. Cherington · Director
  • David H. Deming · Director
  • Ferid D. Murad · Director
  • George P. Denny III · Director
  • John D. Halpern · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 9, 2016. Read the notice at the SEC.

debt, optionsSEC
Apr 2016$2 MNo. 6$2 to $10 million

IRX Therapeutics Inc: Raise no. 6, Apr 2016

Investors in this round

1 investor had bought by the notice of May 13, 2016: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $15 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis P. Robb · Executive Officer
  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer, Director
  • Zygmund P. Roth · Executive Officer
  • Charles R. Cherington · Director
  • David H. Deming · Director
  • Ferid D. Murad · Director
  • George P. Denny III · Director
  • John D. Halpern · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Hwang, President. Source: SEC Form D, newest notice filed May 13, 2016. Read the notice at the SEC.

debt, optionsSEC
Dec 2014$41 MNo. 5$10 to $50 million

IRX Therapeutics Inc: Raise no. 5, Dec 2014

Investors in this round

230 investors had bought by the notice of Aug 17, 2015: 230 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$41 M of $41 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis P. Robb · Executive Officer
  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer, Director
  • Zygmund P. Roth · Executive Officer
  • David H. Deming · Director
  • Ferid D. Murad · Director
  • George P. Denny III · Director
  • John D. Halpern · Director
  • John T. Spitznagel · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Curtis P. Robb, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2015. Read the notice at the SEC.

equitySEC
Feb 2014$15 MNo. 4$10 to $50 million

IRX Therapeutics Inc: Raise no. 4, Feb 2014

Investors in this round

104 investors had bought by the notice of Mar 14, 2014: 104 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $18 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Curtis P. Robb · Executive Officer
  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer, Director
  • Zygmund P. Roth · Executive Officer
  • David H. Deming · Director
  • Ferid D. Murad · Director
  • George P. Denny III · Director
  • John D. Halpern · Director
  • John T. Spitznagel · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC.

debt, optionsSEC
May 2012$2 MNo. 3Under $2 million

IRX Therapeutics Inc: Raise no. 3, May 2012

Investors in this round

105 investors had bought by the notice of May 30, 2012: 105 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$50,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer, Director
  • Ferid W. Murad · Director
  • John T. Spitznagel · Director
  • John W. Hadden · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed May 30, 2012. Read the notice at the SEC.

debt, optionsSEC
May 2010$8 MNo. 2$2 to $10 million

IRX Therapeutics Inc: Raise no. 2, May 2010

Investors in this round

163 investors had bought by the notice of Jun 11, 2010: 163 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Hwang · Executive Officer
  • John W. Hadden II · Executive Officer
  • Ferid W. Murad · Director
  • Frank J. Loverro · Director
  • Howard H. Stevenson · Director
  • John T. Spitznagel · Director
  • John W. Hadden · Director
  • Lawrence M. Wolf · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Jun 11, 2010. Read the notice at the SEC.

debt, optionsSEC
Oct 2009$2 MNo. 1$2 to $10 million

IRX Therapeutics Inc: Raise no. 1, Oct 2009

Investors in this round

33 investors had bought by the notice of Jan 11, 2010: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $6 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Hwuang · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Hwang, Cfo. Source: SEC Form D, newest notice filed Jan 11, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • IRX Therapeutics Inc chose not to state its revenue in its newest notice of a funding round (Aug 2017).

    SEC Form D · Aug 2017

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Aug 2017

That is all the official record says: IRX Therapeutics Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of IRX Therapeutics Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 230 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by IRX Therapeutics Inc
NameRoleNamed in
Curtis P. RobbExecutive officerAug 2017
Mark W. LeuchtenbergerExecutive officerAug 2017
Monil W. ShahExecutive officerAug 2017
Zygmund P. RothExecutive officerAug 2017
Jeffrey HwangExecutive officerJan 2017
John W. Hadden IIExecutive officerJan 2017
Jeffrey HwuangExecutive officerJan 2010
Charles R. CheringtonDirectorAug 2017
David H. DemingDirectorAug 2017
Edmund W. TruellDirectorAug 2017
Ferid D. MuradDirectorAug 2017
George P. Denny IIIDirectorAug 2017
John D. HalpernDirectorAug 2017
Lawrence M. WolfDirectorAug 2017
Mark W. LeuchtenbergerDirectorAug 2017
John W. Hadden IIDirectorJan 2017
John T. SpitznagelDirectorAug 2015
Ferid W. MuradDirectorMay 2012
John W. HaddenDirectorMay 2012
Frank J. LoverroDirectorJun 2010
Howard H. StevensonDirectorJun 2010